PharmaEssentia at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
PharmaEssentia exhibits at Booth 3739 at ASH 2026 in New Orleans. PharmaEssentia supports symposia on myeloproliferative neoplasms that apply new evidence to everyday care. The more specific program zeroes in on essential thrombocythemia and polycythemia vera and how emerging data is changing practice.
| Organization | ASH 2026 Attendance |
|---|---|
PharmaEssentia Taipei, Taiwan | |
Taiwan-based biopharmaceutical company making biologics for hematology and oncology, including an approved interferon therapy for polycythemia vera. | Booth Exhibiting at Booth 3739 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 3:00pm–6:00pm Cases and Conversations™: Applying Emerging Evidence to Real-World Care in Myeloproliferative Neoplasms Choosing among new myeloproliferative neoplasm drugs, including Janus kinase and telomerase inhibitors, hepcidin mimetics, and calreticulin-targeted antibodies. Symposium Fri Dec 11 11:00am–2:00pm Show Me the Data™: Emerging Evidence and Evolving Clinical Practice in Essential Thrombocythemia and Polycythemia Vera Newer options for polycythemia vera and essential thrombocythemia, such as ropeginterferon and rusfertide, and what to do when hydroxyurea fails. |
Instantly find 20 buyers from PharmaEssentia
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction